Mitochondrial DNA as a Biomarker of Sepsis Severity
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Listed as NCT03077672, this observational or N/A phase trial focuses on Infection and Sepsis and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 15 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Mar 2023 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Mar 2022 — Mar 2023 [monthly]
Recruiting
-
Dec 2021 — Mar 2022 [monthly]
Recruiting
▶ Show 10 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting
-
Nov 2019 — Nov 2020 [monthly]
Recruiting
-
Feb 2019 — Nov 2019 [monthly]
Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Apr 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Feb 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- New York Presbyterian Brooklyn Methodist Hospital
- New York Presbyterian Hospital
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Brooklyn, United States
- • New York, United States